Dr. Reddy’s Bachupally unit has two blocks, one is an older block, from which the biosimilar Rituximab was filed, and the other one is for the biosimilar abatacept. Nomura believes that most of the observations are for the new unit and issues at the old one are likely to have been addressed.
